The week in health tech, explained in plain English.Get the free newsletter →
October 25, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

ChristianaCare Hospital President Hicks Named CEO of ACP

LeRoi Hicks, MD, is departing Wilmington, Delaware-based ChristianaCare after 12 years to become executive vice president and CEO of the American College of Physicians, according to Becker's Hospital Review. Hicks announced the move in a June 11 LinkedIn post, writing that he was "deeply grateful" for the chance to serve at the health system.

Hicks most recently led ChristianaCare's Wilmington Hospital as its president. His shift from a hospital operating role to the helm of one of the largest physician membership organizations marks a notable move from delivery-side leadership to professional advocacy and policy. The ACP represents internal medicine physicians and subspecialists and shapes clinical guidelines, payment positions, and workforce priorities.

For ChristianaCare, the exit opens a leadership gap at one of its flagship hospitals. For the ACP, recruiting a sitting hospital president signals continued interest in leaders who understand frontline operations and care delivery, not just association management.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.